GlassScriptPhysician profile
Suraj Bopanna
NPI 1740433291
$4,436.82
in general payments reported to CMS, 2019-2025
29 companies · $290 in 2025
The $290 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,203 · 2020: $262 · 2021: $262 · 2022: $38.92 · 2023: $916 · 2024: $466 · 2025: $290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $844 · Food and Beverage: $828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $843.62 |
| Food and Beverage | $827.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Veran Medical Technologies, INC. | $846.12 | 2019-2020 | |
| Intuitive Surgical, INC. | $843.62 | 2023 | Da Vinci Sp |
| Boehringer Ingelheim Pharmaceuticals, INC. | $474.76 | 2019-2023 | Stiolto Respimat, Spiriva Respimat, Ofev |
| Glaxosmithkline, LLC. | $399.08 | 2019-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $384.64 | 2019-2024 | Breztri, Tezspire |
| Medtronic Vascular, INC. | $248.28 | 2019-2020 | |
| Mylan Specialty L.P. | $147.10 | 2019-2024 | Yupelri |
| Sunovion Pharmaceuticals INC. | $118.98 | 2019 | |
| Grifols USA, LLC | $117.08 | 2024-2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $106.74 | 2019-2024 | Dupixent |
| Philips North America LLC | $103.65 | 2019-2025 | (Ak6) Vest Therapy, Disposable Vest |
| Actelion Pharmaceuticals US, INC. | $83.43 | 2019-2020 | |
| Genzyme Corporation | $77.66 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $76.48 | 2025 | |
| Genentech USA, INC. | $57.96 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $46.65 | 2019 | |
| Amgen INC. | $45.88 | 2024-2025 | Tezspire |
| United Therapeutics Corporation | $45.00 | 2021 | |
| Janssen Pharmaceuticals, INC | $27.35 | 2019 | |
| Ambu INC. | $26.36 | 2024 | |
| Vapotherm INC | $24.29 | 2019 | |
| Mallinckrodt Enterprises LLC | $22.94 | 2019 | |
| Verona Pharma, INC. | $21.72 | 2025 | Ohtuvayre |
| Lilly USA, LLC | $18.47 | 2025 | Zepbound |
| Merck Sharp & Dohme LLC | $18.29 | 2020 | |
| Viatris Specialty LLC | $15.47 | 2025 | Yupelri |
| Shire North American Group INC | $14.23 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.26 | 2019 | |
| Pfizer INC. | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suraj Bopanna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.